Search Results - autoimmune

10 Results

Sort By:

Polypeptides for Stimulation of Immune Response (Adjuvants)

Abstract: HMGN polypeptides belong to the high mobility group (HMG) family of chromosomal binding peptides. HMGN polypeptides typically function inside the cell nucleus to bind to DNA and nucleosomes and regulate the transcription of various genes. HMGN polypeptides also can be released by peripheral blood mononuclear cells. However, the extracellular...

Published: 5/22/2024 | Inventor(s): De Yang, Joost Oppenheim, Michael Bustin

Keywords(s): Autoimmune, HMGN, immune response, immunoadjuvant, POLYPEPTIDES, Vaccine Adjuvant

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Immunology, Application > Therapeutics, TherapeuticArea > Oncology

Fatty Acid Derivatives and Their Use for the Treatment and Prevention of Autoimmune, Inflammatory, and Pain Disorders

Abstract: The discovery and selection of suitable compounds for the treatment and prevention of autoimmune, inflammatory, and pain disorders is a significant challenge. Researchers at National Institute of Aging (NIA) mitigated this issue. They discovered and synthesized numerous novel fatty acid derivatives (novel small molecules) that may ameliorate...

Published: 4/8/2024 | Inventor(s): Christopher Ramsden, Gregory Keyes

Keywords(s): Autoimmune, Inflammation, National Institute on Aging (NIA), Pain, Ramsden

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Immunology

Optimized Monospecific or Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20

Abstract: Patients with chemotherapy-refractory, diffuse large B-cell lymphoma (DLBCL) have poor prognoses. CD19 and CD20 are promising targets for the treatment of B-Cell malignancies. However, despite the initial promising results from anti-CD19 CAR therapy, only 30-35% of patients with DLBCL achieve remissions lasting longer than 2-3 years after...

Published: 8/14/2024 | Inventor(s): James Kochenderfer, Norris Lam

Keywords(s): act, adoptive cell therapy, Autoimmune, B Cell Malignancies, BICISTRONIC, CAR, CD19, CD20, chimeric antigen receptor, Kochenderfer, Leukemia, lymphoma, Monospecific

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Immunology, TherapeuticArea > Oncology

Cancer Therapeutic Agents that Bind to STAT Proteins

Abstract: The National Cancer Institute, Cancer and Inflammation Program seeks parties interested in collaborative research to further co-develop inhibitors of STAT proteins for the treatment of cancer. Signal transducer and activator transcription (STAT) proteins, specifically STAT1, 2, 3, 4, 5a, 5b, and 6, are involved in the cellular and biological...

Published: 4/8/2024 | Inventor(s): Nadya Tarasova, Olga Timofeeva, Vadim Gaponenko, Christopher Michejda, Alan Perantoni, Sergey Tarasov

Keywords(s): Autoimmune, N-terminal domain, STAT

Category(s): TherapeuticArea > Oncology, TherapeuticArea > Immunology, Collaboration Sought > Licensing, Application > Therapeutics

Hydrocarbon Stapled Peptides that Inhibit the Linear Ubiquitin Chain Assembly Complex (LUBAC) for the Therapy of the Activated B Cell-like (ABC) Subtype of Diffuse Large B Bell Lymphoma (A Type of Non-Hodgkin’s Lymphoma)

Abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma and consists of three subtypes: activated B-cell (ABC), germinal center B-cell (GBC), and primary mediastinal B-cell (PMB). Despite advances in the front-line therapy for DLBCL, approximately one-third of patients will relapse. Substantially worse outcomes...

Published: 8/14/2024 | Inventor(s): Louis Staudt, Yiban Yang, Federico Bernal

Keywords(s): ABC DLBCL, Activated B Cell-like, Autoimmune, Bernal, CANCER, Diffuse Large B Cell Lymphoma, INFLAMMATORY, Linear Ubiquitin-chain Assembly Complex, LUBAC, NF-κB, Non-Hodgkin’s Lymphoma, Peptide Inhibitor, Staudt, therapeutic

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Therapeutics, TherapeuticArea > Immunology

RORgamma (RORC) Deficient Mice Which Are Useful for the Study of Lymph Node Organogenesis and Immune Responses

The retinoid-related orphan receptor gamma (RORgamma) is a member of the nuclear receptor superfamily. NIH investigators used homologous recombination in embryonic stem cells to generate mice in which the RORgamma gene was disrupted. RORgamma deficient mice lack peripheral and mesenteric lymph nodes and Peyer's patches indicating that ROR expression...

Published: 10/28/2024 | Inventor(s): Anton Jetten

Keywords(s): Autoimmune, DEFICIENT, Disease, IDXXXX, IMMUNE, IXXXXX, Mice, Responses, RORC, RORgamma, RXXXXX, TOOLS

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, Application > Therapeutics, Application > Research Materials, Application > Diagnostics

Prevention and Treatment of Multiple Sclerosis (MS) by Administering E-Selectin

The invention is a method and composition for inhibiting or treating symptoms of inflammatory demyelination or inflammation associated with autoimmune disorders. This is accomplished by administering recombinant E-selectin protein intranasally and resulting in E selectin-specific regulatory T-cells. These regulatory T-cells suppress activation of blood...

Published: 4/8/2024 | Inventor(s): Jacqueline Shukaliak-Quandt

Keywords(s): ANIMAL, Autoimmune, BBXXXX, BCXXXX, brain, Damage, EAE, Encephalomylelitis, e-selectin, EXPERIMENTAL, IMMUNOLOGICAL, Model, Multiple sclerosis, NB1HXX, NB1JXX, NB1XXX, NBXXXX, NXXXXX, PREVENTS, Tolerization

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Neurology

Muramyl Dipeptide as a Therapeutic Agent for Inflammation

The nucleotide-binding oligomerization domain 2 (NOD2) protein plays a key role in innate immunity as a sensor of muramyl dipeptide (MDP), a breakdown product of bacterial peptidoglycan. Bacterial peptidoglycan promotes the innate immune response through the activation of Toll-like receptor 2 (TLR2), which ultimately provokes inflammation. Activation...

Published: 10/28/2024 | Inventor(s): Warren Strober

Keywords(s): Autoimmune, AUTOIMMUNE DISEASE, Autoimmune disorder, Autoimmunity, BBXXXX, BCXXXX, BOWEL, Crohn disease; Inflammatory bowel disease 1, Crohn's disease, Dipeptide, IB3XXX, IBD, IBXXXX, IL-12, Inflammation, INFLAMMATORY, inflammatory bowel disease, Inflammatory bowel disease 1, inflammatory disease, INTERLEUKIN, INTERLEUKIN-12, IRF4, IXXXXX, MDP, Muramyl, NOD2, peptidoglycan, TLR, TLR2, Toll-like, Toll-like receptors, Ulcerative Colitis

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Immunology, Application > Research Materials, Application > Diagnostics

Antibodies Against TL1A, a TNF-Family Cytokine, for the Treatment and Diagnosis of Autoimmune Inflammatory Diseases

Autoimmune inflammatory diseases occur in greater than five percent of the United States population; this disease group includes asthma, multiple sclerosis, rheumatoid arthritis, and lupus. Treatments generally include immunosuppressants or anti-inflammatory drugs, which can have serious side effects; recently, more specific immunomodulatory therapies...

Published: 12/27/2024 | Inventor(s): Francoise Meylan, Yun-Jeong Song, Richard Siegel

Keywords(s): antibodies, ANTIBODY, ANTI-HUMAN, Anti-mouse, Autoimmune, diagnostic, DR3, IA3XXX, IAXXXX, IB3XXX, IBXXXX, Immunomodulation, immuno-modulator, immunomodulatory, INFLAMMATORY, inflammatory disease, IXXXXX, monoclonal, Monoclonal Antibodies, Monoclonal Antibody, Patent Category - Biotechnology, therapeutic, TL1A, tnf, TNFRSF25, TNFSF15, tumor necrosis factor, USES

Category(s): Application > Research Materials, Application > Therapeutics, Application > Diagnostics, TherapeuticArea > Immunology

A Novel Rapid Point-of Care Diagnostic Method for Infectious and Autoimmune Diseases

Rapid point-of-care, antibody-based testing is not available for the diagnosis of autoimmune and most infectious diseases. For detecting autoantibodies associated with most autoimmune conditions, fluid-phase immunoprecipitation assays are required. However, these assays usually involve radioactivity and are not feasible for point-of-care applications....

Published: 12/31/2024 | Inventor(s): Peter Burbelo

Keywords(s): Autoimmune, Diagnosis, DISEASES, INFECTIOUS, Magnet, Methods, Neodymium, RAPID, VAXXXX, VFXXXX, VJXXXX, VKXXXX, VLXXXX, VQXXXX, WBXXXX, XAXXXX, XDXXXX, XHXXXX, YAXXXX, YBXXXX, YFXXXX

Category(s): TherapeuticArea > Endocrinology, TherapeuticArea > Immunology, Application > Non-Medical Devices, Application > Medical Devices, TherapeuticArea > Geriatrics, TherapeuticArea > Infectious Disease, ResearchProducts > Research Equipment, Application > Diagnostics, ResearchProducts > Antibodies